In 2015 and 2016, respectively, the Systolic Blood Pressure Intervention Trial (SPRINT) and Heart Outcomes Prevention Evaluation (HOPE)–3 blood pressure (BP) trial published different conclusions.1,2 In SPRINT, more intensive BP reduction than is recommended resulted in a 25% reduction for the primary outcome, a composite based on first occurrence of nonfatal myocardial infarction, non–myocardial infarction acute coronary syndrome, stroke, acute decompensated heart failure, or cardiovascular disease (CVD) death.1 In addition, all-cause mortality was reduced by 27%. The SPRINT findings led to stopping the trial early. In HOPE-3, BP lowering had no significant effect on either of the 2 coprimary CVD composite outcomes (MI, stroke, or CVD death and these plus resuscitated cardiac arrest, HF, and revascularization).2
Whelton PK, Reboussin DM, Fine LJ. Comparing the SPRINT and the HOPE-3 Blood Pressure Trial. JAMA Cardiol. 2016;1(8):855–856. doi:10.1001/jamacardio.2016.2051
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: